Compulsive buying disorder (CBD) — also called buying-shopping disorder or shopping addiction — is a pattern in which a person’s relationship with shopping becomes difficult or impossible to control. It goes well beyond enjoying shopping or occasionally overspending. For people experiencing CBD, the urge to buy feels overwhelming, and the behavior continues even when it causes serious harm to finances, relationships, or daily life.
CBD shares features with several recognized condition families. It resembles obsessive-compulsive disorder in the anxiety-driven, ritualistic quality of the buying urge-and-relief cycle. It parallels impulse control disorders in the failure to resist a mounting urge despite awareness of harmful consequences. And it shares tolerance, craving, loss of control, and affective dysregulation with behavioral addictions. Most contemporary frameworks position CBD along an impulsive-compulsive continuum, placing it closer to the impulsive pole — alongside pathological gambling — while acknowledging that its compulsive features meaningfully complicate that placement.
CBD is described in the clinical literature as a condition associated with functional impairment and substantial psychiatric comorbidity. Its absence from DSM-5 and ICD-11 reflects ongoing efforts to reach consensus on a single standardized definition — not scientific doubt about its existence or clinical significance. Clinicians can currently document CBD under residual categories in both systems (e.g., “Other Specified Disruptive, Impulse-Control, and Conduct Disorder” in DSM-5) while awaiting formal recognition.
Estimated population prevalence ranges from approximately 4–6% in general adult samples, based on a 2016 meta-analysis (Maraz et al.) across 40 studies. Prevalence estimates vary substantially depending on assessment instrument and whether functional impairment criteria are strictly applied.
Disproportionately identified in female populations in most study samples, though male underreporting is a recognized methodological limitation.
Typically in late adolescence to early adulthood; often preceded by years of subclinical pattern escalation.
E-commerce and app-based retail environments are increasingly implicated in both onset and escalation.
Important caveat: The neurobiological evidence specific to CBD is largely inferential — drawn from behavioral patterns, pharmacological response data, and analogy with better-studied behavioral addictions — rather than from dedicated neuroimaging studies of CBD populations. This is a material gap in the literature that limits mechanistic conclusions. Within those constraints, the available evidence is consistent with dopaminergic reward pathway involvement. Shopping-related stimuli appear to activate mesolimbic circuitry in ways that parallel patterns observed in other reward-driven behaviors. Repeated engagement may produce neuroadaptation over time, manifesting clinically as tolerance — a progressive escalation in purchasing activity required to achieve equivalent affective relief.
CBD rarely occurs in isolation. Mood disorders — particularly major depressive disorder and dysthymia — represent the most prevalent co-occurring conditions, followed by anxiety disorders spanning social phobia, panic disorder, generalized anxiety disorder, OCD, and PTSD. Eating disorders, particularly binge eating disorder, appear with notable frequency, suggesting possible shared mechanisms involving impulsive consumption and affective dysregulation. Substance use disorders and other behavioral addictions are also significantly overrepresented. A substantial proportion of individuals with CBD meet criteria for a comorbid personality disorder, with obsessive-compulsive, borderline, and avoidant types most commonly reported. The relationship between CBD and mood and anxiety conditions is bidirectional: depression and anxiety may drive shopping as a mood-regulation strategy, while the financial consequences and shame of CBD may maintain and worsen those same conditions. Comorbidity severity appears to scale with CBD severity.
A consistent psychological vulnerability profile has emerged from research. Individuals who develop CBD characteristically present with low baseline self-esteem, a compensatory orientation toward materialism, and a pattern of using acquisition as a primary strategy for regulating negative affect. Elevated impulsivity — spanning cognitive and motor domains — is a reliably identified characteristic; the disproportion between high urge intensity and low inhibitory control is a more specific predictor of pathological buying than the urge alone. The digital retail environment represents a materially distinct and escalating risk factor. E-commerce design features — one-click purchasing, frictionless checkout, 24/7 availability, algorithmic product personalization, and push notification systems — directly operationalize the conditions under which compulsive buying urges are most readily triggered and least likely to be interrupted. The role of consumer technology in onset and maintenance is increasingly documented and warrants explicit clinical attention. There is emerging evidence that CBD may run in families to some degree, though whether this reflects shared genetics, shared environments, or both remains unestablished.
CBT for CBD targets the cognitive distortions linking acquisition with self-worth, develops affect tolerance and alternative emotion regulation strategies, and builds behavioral self-management skills. A manualized protocol — twelve sessions over ten weeks — demonstrated significant reductions in buying episode frequency in a small controlled study. Group therapy formats offer additional benefit through practical skill-building, and may be particularly helpful given the social isolation and shame that frequently impede help-seeking. Motivational Interviewing is a useful adjunct when ambivalence about change is prominent. In the pharmacological domain, selective serotonin reuptake inhibitors (SSRIs) have been most extensively studied, reflecting CBD's conceptual overlap with OCD and depressive spectrum conditions. Open-label data suggested meaningful reductions in shopping preoccupation and urge intensity; however, controlled trials showed high placebo response rates that substantially complicate interpretation. No pharmacological agent carries regulatory approval specifically for CBD. Treating confirmed comorbid conditions (depression, anxiety, OCD) frequently produces collateral improvement in CBD symptomatology and should be prioritized where indicated.